Pennant Group, Inc.
- PNTG · Nasdaq
- Services-Health Services
- Eagle, ID
- 9,700 employees
- CIK 0001766400
Updated from SEC filings through
Top things to know
Executives
- Brent Guerisoli The Company’s Chief Executive Officer 8-K, 2026-11-04
- Lynette Walbom Chief Financial Officer 4/A, 2026-04-17
- Lynette B. Walbom Chief Financial Officer 10-K, 2026-02-26
- John Gochnour The Company’s Chief Operating Officer 8-K, 2026-11-04
- Jason Paul Steik Chief Clinical Officer 4, 2026-08-10
- John J. Gochnour Chief Operating Officer 4/A, 2026-04-17
What leadership is saying
“Pennant delivered a solid quarter and strong year-over-year improvement across the organization”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
Pennant Group, Inc. is a U.S. public company in services-health services (SIC 8000), headquartered in Eagle, ID. It trades as PNTG on Nasdaq. Revenue was $948M in the fiscal year ending December 31, 2025, +36.3% from the year before. It reported about 9,700 employees. Brent Guerisoli is The Company’s Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $948M 10-K, 2026-02-26 | $695M 10-K, 2026-02-26 | $545M 10-K, 2026-02-26 | $473M 10-K, 2025-02-27 | $440M 10-K, 2024-02-28 |
| Operating income | $51.9M 10-K, 2026-02-26 | $38.1M 10-K, 2026-02-26 | $25.2M 10-K, 2026-02-26 | $12.7M 10-K, 2025-02-27 | $4.7M 10-K, 2024-02-28 |
| SG&A | $71.1M 10-K, 2026-02-26 | $50.2M 10-K, 2026-02-26 | $36.7M 10-K, 2026-02-26 | $34.0M 10-K, 2025-02-27 | $36.3M 10-K, 2024-02-28 |
| Net income | $29.6M 10-K, 2026-02-26 | $22.6M 10-K, 2026-02-26 | $13.4M 10-K, 2026-02-26 | $6.6M 10-K, 2025-02-27 | $2.7M 10-K, 2024-02-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Brent Guerisoli | The Company’s Chief Executive Officer | 8-K, 2026-11-04 |
| Lynette Walbom | Chief Financial Officer | 4/A, 2026-04-17 |
| Lynette B. Walbom Chief Financial Officer at Pennant | Chief Financial Officer | 10-K, 2026-02-26 |
| John Gochnour | The Company’s Chief Operating Officer | 8-K, 2026-11-04 |
| Jason Paul Steik | Chief Clinical Officer | 4, 2026-08-10 |
| John J. Gochnour President and Chief Operating Officer at The Pennant Group, Inc. | Chief Operating Officer | 4/A, 2026-04-17 |
| Jason P. Steik | Named in proxy bio: Chief Clinical Officer | DEF 14A, 2026-03-31 |
| Kirk Sterling Cheney | EVP, GC and Corp Secy | 4, 2026-08-10 |
| Kirk S. Cheney | Named in proxy bio: EVP, General Counsel and Corporate Secretary | DEF 14A, 2026-03-31 |
| Barry M. Smith | Director | 10-K, 2026-02-26 |
| Christopher R. Christensen | Director | 10-K, 2026-02-26 |
| Gregory K. Morris M.D. | Director | 10-K, 2026-02-26 |
| John G. Nackel, Ph.D. | Director | 10-K, 2026-02-26 |
| Scott E. Lamb | Director | 10-K, 2026-02-26 |
| Stephen M. R. Covey | Director | 10-K, 2026-02-26 |
| Suzanne D. Snapper | Director | 10-K, 2026-02-26 |
What Pennant Group, Inc. does
The Pennant Group, Inc. is a leading provider of high-quality healthcare services to patients, residents, and clients of all ages, including the growing senior population, in the United States. We strive to be the provider of choice in the communities we serve through our innovative operating model and unique core values.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 35.1 million (as of November 2, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $989M (as of June 30, 2025) | 10-K, February 26, 2026 |
| Latest proxy statement | Meeting May 14, 2026 (filed March 31, 2026) | DEF 14A, March 31, 2026 |
| Auditor | Deloitte & Touche LLP (Boise, ID) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 6, 2026 | Jason Paul Steik Chief Clinical Officer | Sale | 1,394 | $54K | Form 4, August 10, 2026 |
| August 6, 2026 | Brent Guerisoli Chief Executive Officer | Sale | 4,285 | $165K | Form 4, August 10, 2026 |
| August 6, 2026 | Kirk Sterling Cheney EVP, GC and Corp Secy | Sale | 1,393 | $54K | Form 4, August 10, 2026 |
| July 10, 2026 | Brent Guerisoli Chief Executive Officer | Sale | 3,159 | $131K | Form 4, July 14, 2026 |
| July 7, 2026 | Brent Guerisoli Chief Executive Officer | Sale | 3,165 | $128K | Form 4, July 9, 2026 |
| May 22, 2026 | Brent Guerisoli Chief Executive Officer | Sale | 4,508 | $158K | Form 4, May 27, 2026 |
| July 28, 2025 | Kirk Sterling Cheney EVP, GC and Corp Secy | Sale | 880 | $21K | Form 4, August 7, 2025 |
| July 28, 2025 | Brent Guerisoli Chief Executive Officer | Sale | 3,995 | $93K | Form 4, July 31, 2025 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-20
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-25
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-11-05
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2025-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-10-02
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2025-10-02
- Item 2.01 Completion of acquisition or disposition of assets
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Pennant Group, Inc.
- What does Pennant Group, Inc. do?
- In its own words, from Item 1 of its 10-K: "The Pennant Group, Inc. is a leading provider of high-quality healthcare services to patients, residents, and clients of all ages, including the growing senior population, in the United States. We strive to be the provider of choice in the communities we serve through our innovative operating model and unique core values."
- What is Pennant Group, Inc.'s revenue?
- $948M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Pennant Group, Inc. profitable?
- Pennant Group, Inc. reported net income of $29.6M for the fiscal year ending December 31, 2025.
- How many employees does Pennant Group, Inc. have?
- About 9,700 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Pennant Group, Inc.?
- Brent Guerisoli, The Company’s Chief Executive Officer, as named in a 8-K filed November 4, 2026.
- Who is the CFO of Pennant Group, Inc.?
- Lynette Walbom, Chief Financial Officer, as named in a 4/A filed April 17, 2026.
- Where is Pennant Group, Inc. headquartered?
- Eagle, ID.
- What is Pennant Group, Inc.'s stock ticker?
- PNTG on Nasdaq.
- What industry is Pennant Group, Inc. in?
- Services-Health Services, SIC code 8000.
- What is Pennant Group, Inc.'s website?
- pennantgroup.com.
- When does Pennant Group, Inc. report earnings next?
- February 3, 2027. Source: estimate_8k_pattern.
- Is Pennant Group, Inc. a public company?
- Yes. Pennant Group, Inc. files with the SEC under CIK 0001766400 and trades as PNTG.
- Who audits Pennant Group, Inc.?
- Deloitte & Touche LLP, Boise, ID, as named in its latest annual report (10-K).
- How many shares of Pennant Group, Inc. are outstanding?
- 35.1 million shares as of November 2, 2026, from its 10-Q filed November 4, 2026.
- What is Pennant Group, Inc.'s public float?
- $989M as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- When is Pennant Group, Inc.'s annual shareholder meeting?
- May 14, 2026, per its proxy statement (DEF 14A) filed March 31, 2026.
- Have Pennant Group, Inc. insiders traded stock recently?
- Since July 28, 2025, officers and directors reported 8 open-market sales worth about $804K and 0 purchases on Forms 4 and 5. The most recent: Jason Paul Steik (Chief Clinical Officer) sold 1,394 shares on August 6, 2026.